In this regard, in the study of Crawford et al. published in 1999 (18), involving patients diagnosed with lung cancer and treated with cyclophosphamide, etoposide and doxorubicin, the percentage of patients who developed oral mucositis was seen to be lower in the group treated with subcutaneous G-CSF than in the control group (53% versus 70%, respectively). Here, CSF3 is linked to lung carcinoma.